These data suggest a potential rationale for combined targeting of NR2F6 and PD-L1/PD-1 in human cancer and may hint at a specific immunological fingerprint helping to select or stratify patients for the most appropriate immune-activating therapeutic strategy. This evidence concerns the gene PDCD1 and cancer.